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Background: SSRIs (Selective Serotonin Reuptake Inhibitors) are the most useful drugs
to treat depression during pregnancy. Intrauterine exposure to SSRIs may increase the
risk of growth restriction, preterm birth and neonatal complications. However, advantages
in treating depression seem to exceed potential drug side effects in respect un-treated
depression. SSRIs undergo extensive hepatic first-pass metabolism with the involvement
of several cytochrome P450 (CYPs) enzymes. Genetic polymorphisms may influence
the expression and activity of CYPs genes. The first aim of this study was to evaluate
neonatal outcomes in depressed mothers exposed to SSRIs during pregnancy. SSRIs
pharmacogenetics was also evaluated in a subset of mothers and fetuses.
Methods: In this case-control study, cases (n = 42) were Caucasian women with a
diagnosis of depression and/or anxiety, treated with SSRIs for the whole pregnancy.
Controls (n = 85) were Caucasian women without a psychiatric diagnosis and not
exposed to SSRIs during pregnancy. Exclusion criteria for both groups were other
psychotropic drugs, anti-epileptics, drug of abuse, alcohol addiction, maternal or fetal
infectious diseases, fetal/neonatal chromosomal genetic abnormalities. Maternal and
fetal blood samples were obtained at delivery to analyze genotype in 33 cases.
Results: The population was homogenous for demographic, anthropometric,
socio-economic and obstetric variables except for smoking andmean hemoglobin values
before delivery. Obstetric features were comparable. Newborns exposed to SSRIs during
fetal life were significantly more likely to be Low Birth Weight (LBW) (birth weight<2,500 g)
(p = 0.01), had significantly lower mean Apgar scores at 1’ (p = 0.006) and at 5’
(p = 0.023) and worse Apgar distribution at 1’ (p = 0.017) and at 5’ (p = 0.013).
Fifty-six percent of newborns presented one or more symptoms consistent with poor
neonatal adaptation syndrome (PNAS). Pharmacogenetic analysis at delivery did not
show significant differences in the frequencies of obstetric or neonatal complications
in relation to polymorphisms.
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Conclusions: We found that newborns exposed to SSRIs are at increased risk of
poor neonatal outcomes in terms of low birth weight, low Apgar scores and, clinically,
poor neonatal adaptation syndrome. Preliminary pharmacogenetic analysis showed
that the degree of CYPs alterations, that depends on polymorphisms, may influence
neonatal outcomes.
Keywords: SSRI, pharmacogenetics, poor neonatal adaptation syndrome, newborns, pregnancy, depression
INTRODUCTION
Recent studies have shown that 2–9% of women in the Western
world are prescribed antidepressants (AD) during pregnancy (1).
Intrauterine exposure to antidepressant drugs may have adverse
consequences for birth outcome and child development (2, 3).
Antidepressants use during pregnancy can lead to increased
risk of miscarriage, congenital cardiac malformations, preterm
birth (PTB), persistent pulmonary hypertension of the newborn
(PPHN), and poor neonatal adjustment syndrome (PNAS) (4, 5).
Multiple studies have reported an increased risk of PTB (OR
ranging from 1.5 to 2) with prenatal exposure to antidepressants
(6). It has been reported a possible increased risk of delayed
neurobehavioral development in children (7). Several recent
systematic reviews and meta-analyses emphasize that there are
minimal definitive conclusions to guide treatment (8). In this
view it is important to evaluate potential neonatal risks such that
pregnant women can be provided with better counseling and
midwives and pediatricians alerted at delivery.
Exposure to untreated depression and stress during pregnancy
may have negative consequences for birth outcome and child
development (9). Suicidal ideation also can be elevated in
pregnant women with depression, representing a real risk for the
life of both the mother and the fetus (10, 11).
Selective serotonin reuptake inhibitors (SSRIs) are the drug
of choice, for their safety profile, in terms of fewer metabolites,
higher protein binding to decrease placental passage, and
fewer interactions with other medications (12). Sertraline,
paroxetine, fluoxetine, fluvoxamine citalopram, and escitalopram
are included in this group.
Results of studies examining the effects of antidepressants
exposure on birth outcomes and child development have been
inconsistent, since the contribution from the underlying mood
disorder and the associated behaviors (e.g., poor prenatal health
behaviors, concomitant medications, smoking, substance abuse,
and obesity) may be confounding variables (6).
In pregnancy there are changes in drugs absorption,
distribution, metabolism, and elimination. Therefore,
antidepressants dosage should be increased to maintain a
therapeutic effect (13, 14). Fetal exposure to antidepressants
occurs through umbilical cord blood flow, placental transport,
Abbreviations: BMI, Body Mass Index; CYP, cytochrome P; LBW, low birth
weight; OR, odds ratio; PNAS, poor neonatal adaptation syndrome; PPHN,
Persistent Pulmonary Hypertension of the Newborn; PTB, preterm baby; RDS,
respiratory distress syndrome; SD: standard deviation; SGA, small for gestational
age; SSRIs, selective serotonine inhibitors; TDM, therapeutic drug monitoring;
TTN, Transient Tachypnea of the Newborn.
and absorption from amniotic fluid. This is influenced by the
cord-to-maternal ratio of the antidepressant level, their half-life
and peak levels, genetic polymorphisms of drug metabolism
enzymes and transporter proteins, and the unbound fraction of
antidepressant in the fetus (15).
SSRIs undergo extensive hepatic first-pass metabolism with
the involvement of several cytochrome P450 (CYPs) enzymes.
Expression of CYPs genes is influenced by a combination
of factors including genetic polymorphisms, drug-drug
interactions, patients’ age. Distinct CYPs pharmacogenetic
phenotypes, derived from polyallelic mechanisms, have been
associated to the dose requirement, drug efficacy and occurrence
of severe toxicities (16, 17).
We recently reported preliminary observations on the
contribution of individual pharmacogenetics of SSRIs on infants’
outcome. We also estimated the umbilical/maternal plasma SSRI
concentration ratio at delivery (18).
The primary aim of this study was to evaluate neonatal
outcomes in depressed mothers exposed to SSRIs during
pregnancy.We also evaluated SSRIs pharmacogenetics in a subset
of mothers and fetuses.
METHODS
This was a prospective, observational, and experimental case-
control study. It was performed from January 2011 to May 2016
in the Unit of Obstetrics-Gynecology, Sacco Hospital, Milan in
collaboration with the Units of Neonatology and Pharmacology.
The Medical Ethics Committee of Sacco Hospital approved the
study protocol and the consent procedure. All women gave
their written informed consent for their own and on behalf of
their newborns.
Forty-nine cases and 100 controls were prospectively enrolled.
Cases were Caucasian women with a diagnosis of depression
and/or anxiety in treatment with selective serotonin reuptake
inhibitors (SSRIs) before conception. Venlafaxine was considered
as an SSRI if being dosed <200. We also included in
the study women taking anxiolytics such as benzodiazepines,
if needed.
The control group included Caucasian women, not exposed
to psychotropic medications before and during pregnancy.
Two unexposed subjects per one SSRI-exposed subject were
randomly selected from the delivery register of the hospital,
by taking the first two deliveries immediately after each
SSRI case.
The exclusion criteria were the use of other psychotropic
drugs (besides SSRIs or sporadic benzodiazepines), anti-epileptic
Frontiers in Pediatrics | www.frontiersin.org 2 July 2019 | Volume 7 | Article 309
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
Corti et al. Intrauterine Exposure to Antidepressants
drugs, drug of abuse or alcohol addiction, maternal or
fetal infectious diseases, fetal/neonatal chromosomal genetic
abnormalities. Women who stopped taking medication before or
during labor were excluded from the study.
Out of the 48 enrolled cases, two were lost to follow-up,
two were excluded because in treatment with antipsychotics or
antidepressants other than SSRI, and two had not yet delivered at
the end of the study, leaving 42 cases with 42 newborns.
All cases were followed in a prospective way by our
multidisciplinary team, that checked drug compliance,
psychologic clinical control and maternal and fetal well-being at
each visit during the whole pregnancy up to delivery.
Maternal and fetal data of the control group were collected
from the registers and databases of Sacco Hospital. Forty-two
cases were compared to 85 controls for neonatal outcomes.
We evaluated and compared pregnancy complications
such as Gestational Diabetes, Intrauterine Growth Restriction
(IUGR), Pregnancy Induced Hypertension, Cholestasis of
pregnancy, Preterm Premature Rupture of Membranes
(pPROM), Hyperemesis Gravidarum, Polyhydramnios,
Oligohydramnios, Anhydramnios, and delivery outcomes
in the two groups, including variables such as mode of delivery,
urgent cesarean section, vacuum-assisted vaginal delivery,
induction of labor, epidural anesthesia, meconium-stained
amniotic fluid third degree.
We evaluated neonatal anthropometric characteristics
such as birthweight, neonatal sex, gestational age at birth,
Apgar score at 1 and 5min, umbilical artery pH and base
excess (BE) at blood gas analysis on cord blood. Neonatal
complications considered in this study were Intrauterine
Growth Restriction (IUGR), preterm birth, low birth weight
(LBW), Small for Gestational Age (SGA), Apgar scores at 1’
and 5’ lower than 7, neurologic symptoms, Respiratory Distress
Syndrome (RDS), Hypoglycemia, malformations, access to
Neonatal Intensive Care Unit, and Poor Neonatal Adjustment
Syndrome (PNAS).
SSRI’s pharmacogenetics were evaluated by analyzing cases’
maternal and blood samples that were collected at delivery.
Fetal samples were collected from cord blood. Immediately after
withdrawal, each blood sample was collected in a vial with
sodium citrate and kept on ice until centrifugation. Samples
were stored at −20◦C for further genotyping at the centralized
pharmacogenetics laboratory of the Pharmacology Unit of
Sacco Hospital.
Of 42 cases, 35/42 valid samples were collected for genotyping,
and 32 maternal and neonatal samples were included in the
pharmacogenetic analysis focused at the time of delivery.
Three mothers had some missing data (nd) relatively to
genotype (Figure 1).
Genomic DNA was isolated from peripheral blood cells using
an automatic DNA extraction system (Maxwell R⃝ 16 System,
Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Polymorphisms were determined by Real-Time
PCR using LightSNiP R⃝ (TIB-MolBiol, Berlin) or TaqMan R⃝
assay (Thermo Fisher Scientific, Waltham, MA, USA) according
the manufacturer’s instructions. We selected and evaluated
the functional variants mapping in CYP2D6 (∗3,∗4,∗5,∗6,
FIGURE 1 | Study population.
rs1080985 promoter variant, gene duplication) for paroxetine,
venlafaxine and citalopram, CYP2C19 (∗2, ∗3, ∗17) for sertraline
and citalopram, CYP2B6∗6 for sertraline, CYP3A4∗22 and
CYP3A5∗3 for citalopram (19).
Statistical Analysis
Results are reported as mean values± standard deviation (SD).
Maternal and fetal characteristics were compared between
groups using independent-samples t-test. Levene’s test for
equality of variances was performed to assess whether data
were obtained from populations of equal/unequal variances.
Chi-square analyses were performed to compare characteristics
expressed as frequencies. Analyses were considered significant
when p < 0.05. Tests were performed by statistical package SPSS
(IBM-SPSS-Statistics 21.00, Armonk, NY).
RESULTS
One hundred twenty-seven pregnant women were studied 42
of whom in treatment with SSRIs (cases) and 85 without
(controls). The control population showed similar demographic,
anthropometric and socio-economic features, except for smoking
(Table 1); higher rates of smoking among depressed women
compared to women without a psychiatric diagnosis were
previously reported. We did not find relevant differences
in major comorbidities prevalence, such as hypertension or
diabetes mellitus.
In the SSRIs population depressive disorder, including both
major and minor ones, accounted for 43% of the cases, anxiety
disorders, including generalized anxiety, panic and obsessive-
compulsive disorders for 26%, mixed anxiety-depressive disorder
for 26%, and bipolar ones for 5%. Sertraline (40%) and paroxetine
(31%) were the two most used molecules accounting together for
more than 80%. Nineteen percent of patients had also received
prescription for an anxiolytic drug belonging to the family of
benzodiazepines for sporadic use.
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TABLE 1 | Characteristics of the population.
Controls
(n = 85)
SSRIs
(n = 42)
p-value
Age (years) 32.7 ± 5.9 34.4 ± 5.2 NS
Pregestational Body Mass
Index (Kg/m²)
23.4 ± 4.5 23.9 ± 4.9 NS
Gestational weight gain (Kg) 11.8 ± 5.0 12.6 ± 4.7 NS
Smoking (any quantity) 3.0 (3.5%) 7.0 (16.7%) 0.012
Marital status NS
Married 57 (67.1%) 29 (69.0%)
Not married 28 (32.9%) 13 (31.0%)
Single 0 0
Occupational status NS
Occupied 60 (70.6%) 33 (78.6%)
Not occupied 25 (29.4%) 9 (21.4%)
Parity NS
Primiparous 30 (35.3%) 19 (45.2%)
Multiparous 55 (64.7%) 23 (54.8%)
Multiple pregnancy (twins) 1 (1.2%) 1 (2.4%) NS
Onset of pregnancy NS
Spontaneous 81 (95.3%) 41 (97.6%)
ART 4 (4.7%) 1 (2.4%)
Data are presented as mean (± SD) or as number of women (%).
p: NS = not significant, < 0.05 = significant.
SSRIs, selective serotonin reuptake inhibitors.
ART, assisted reproductive technology.
Pregnancy complications and obstetric outcomes were similar
in the two groups, as shown in Table 2 and Figure 2.
The SSRIs group presented statistically relevant higher rates
of low birth weight newborns (14.3%, p = 0.01) and significantly
lower Apgar scores at 1 and 5min after delivery (p = 0.00 and
p = 0.02). Higher scores were more prevalent in controls than
in cases, whereas the lowest scores were registered only in cases
(p = 0.01). Neonatal sex was not a discriminant factor (Table 3).
Incidence of other neonatal complications in the two groups was
not statistically relevant.
Table 4 presents neonatal outcomes in relation to thematernal
and fetal genotypes. No significant difference was observed in
neonatal outcomes in relation to either genotype.
DISCUSSION
This study shows that newborns exposed to SSRIs during fetal life
are at increased risk of poor neonatal outcomes, in terms of low
birth weight, low Apgar scores, and poor neonatal adaptation
syndrome. The case-control population showed similar
demographic, anthropometric and socio-economic features,
except for smoking. Higher rates of smoking among depressed
women, compared to women without a psychiatric diagnosis,
were reported in previous studies (20–23). It is not clear if
smoking may be related with depression. Levels of dopamine
are often low in people with depression, and these individuals
TABLE 2 | Pregnancy and obstetric outcomes.
Controls
(n = 85)
SSRIs
(n = 42)
p-value
Gestational age at delivery (weeks) 39.4 ± 1.3 39.0 ± 1.6 NS
Pregnancy complications, n. (%) 25 (29.4%) 16 (38.1%) NS
Vaginal delivery, n. (%) 57 (67.1%) 22 (52.4%) NS
Cesarean section, n. (%) 28 (32.9%) 20 (47.6%) NS
Spontaneous vaginal delivery, n. (%) 55 (64.7%) 20 (47.6%) NS
Vacuum-assisted vaginal delivery, n. (%) 2 (2.4%) 2 (4.8%) NS
Elective cesarean section,
n. (%)
14 (16.5%) 9 (21.4%) NS
Urgent cesarean section,
n. (%)
14 (16.5%) 11 (26.2%) NS
Inductions, n. (%) 26 (30.6%) 8 (19.0%) NS
Epidural anesthesia, n. (%) 24 (28.2%) 10 (23.8%) NS
Meconium-stained amniotic fluid 3rd
degree, n. (%)
1 (1.2%) 0 NS
Shoulder dystocia 0 0 NS
Perineal laceration 3rd degree, n. (%) 1 (1.2%) 0 NS
Data are presented as mean (± SD) or as number of women (%).
p: NS = not significant, < 0.05 = significant.
SSRIs, Selective Serotonin Reuptake Inhibitors.
Pregnancy complications: pPROM, IUGR, Hyperemesis, Cholestasis of pregnancy,
Polyhydramnios, Oligohydramnios, Anhydramnios, Pregnancy Induced Hypertension,
Gestational Diabetes.
Complications at delivery: perineal lacerations III or IV degree, meconium stained amniotic
fluid, shoulder dystocia.
may then use cigarettes as a way of temporarily increasing their
dopamine supply, in order to increase pleasurable feelings (24).
The distribution of the psychiatric diagnosis in this study
was in line with epidemiological data (25). Depressive disorders
accounted for 43% of the diagnosis, followed by anxiety disorders
(26%) and mixed anxiety-depressive disorder (26%). Only 5% of
patients had a bipolar diagnosis. Also the use of drugs was in line
with epidemiological data with sertraline as the most frequent
drug (26). This is because of its short half-life and consequent
easier use and safer profile in pregnancy.
Neonatal sex was not a discriminant factor nor a bias for
the results. Low birth weight newborns were significantly more
frequent in the SSRIs group compared to the control (14.3
vs. 1.2%). These findings are in line with previous studies,
reporting a significant association between antidepressant use in
pregnancy and LBW and PTB (5, 27–29). Both PTB and LBW
can also be a consequence of the underlying psychiatric disorder
(4, 7, 20–22, 30). However, most studies used prescription and
pharmacy dispensation data to classify exposed and not exposed,
but the adherence to the prescribed treatment was unknown
(30). Moreover, most studied retrospective data from national
registers (20, 21, 30) and others did not consider the degree of
the underlying psychiatric disorder (30). These limitations are
not present in this study.
Smoking may be a confounder of this result, since it can cause
LBW (31, 32) and in this study smoking rates were relevantly
different between groups.
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FIGURE 2 | Pregnancy complications in the study population. Data are presented as percentage of women (%) on the population. SSRIs, selective serotonin reuptakeQ3
inhibitors; IUGR, intrauterine growth restriction; pPROM, preterm premature rupture of membranes.
In this study, Apgar scores at 1 and 5min after delivery
were significantly lower in the SSRIs group. Besides averages,
differences in APGAR score distribution were more significant:
higher scores were more prevalent in controls than in cases,
whereas the lowest scores were registered only in cases (p
= 0.01). Clinically, these newborns experienced symptoms
related to poor neonatal adjustment syndrome (PNAS),
respiratory distress syndrome (RDS) or transient tachypnea of
the newborn (TTN). PNAS was clinically defined as Finnegan
score ≥ 8 in three consecutive measurements in newborns
with suggestive clinical presentation (i.e., jitteriness, poor
muscle tone, weak cry, respiratory distress, hypoglycemia,
low Apgar scores, and seizures) (33). It accounted for
56% of newborns and was the most represented adverse
outcome. The most represented symptoms (47%) were the
neurological ones including: tremors, irritability, hyper-
hypotonus, hyperreflexia, jitteriness, restlessness. Respiratory
distress requiring oxygen supplementation was present in 5
newborns, none manifested pulmonary hypertension or seizures.
All these side effects were transient and resolved within a
couple of months. Seven newborns required admission in the
neonatal ward.
It is unclear what causes PNAS. The fact that SSRIs cross
the placenta may be an underlying pathophysiologic mechanism
through possible increases in serotonin concentrations in the
developing fetus. Increased serotonin concentrations may in
turn impact on fetal cardiovascular, respiratory and neurological
development. Accumulation of the antidepressant in the
neonate could lead to serotonergic toxicity. Finally, the abrupt
discontinuation of neonate exposure to the antidepressant
occurring at delivery may cause withdrawal signs (34).
These findings are in agreement with recent studies showing
that treatment of maternal psychiatric disorders with SSRIs
during pregnancy is related to higher risk of respiratory
distress or neonatal maladaptation. In particular, higher risk
of neonatal problems, low Apgar scores, breathing problems,
access to neonatal care unit, and longer hospital staying have
been reported (21, 34–41). However, some of these studies
had a number of limitations in the study design and in
the selection of the included population: most studies were
retrospective (38) or drew data from several national registers
(36); others collected data from different hospitals (36, 38) and
considered a not homogenous population (38). Finally, some
studies did not take into account confounding variables, as the
underlying maternal psychiatric condition, potentially leading
to misclassification bias (40), or maternal Body Mass Index
(BMI) (36).
These limitations were not present in this study, since
data were prospectively collected in one single hospital with
the same procedures and the same multidisciplinary medical
team. Moreover, the population of this study was homogeneous
and evaluated for confounding variables, as the underlying
psychiatric diagnosis and maternal BMI. These were main
strengths of this study. Another point of strength of this
study was that the analysis of neonatal outcomes included
anthropometric and short-term clinical outcomes, and their
relation with maternal and fetal pharmacogenetic variables.
Indeed, maternal and fetal genotypes of genes involved
in SSRIs metabolism were evaluated in relation to neonatal
outcomes. Due to little sample size, we did not find
significant differences. However, as we previously reported,
we observed three cases with an altered polymorphism
that was associated to an altered pharmacokinetic
resulting in neonatal toxicity (18). Our hypothesis is
that maternal and fetal functional polymorphisms in
genes involved in SSRIs metabolism could affect their
pharmacokinetics—how much drug is transferred to the
fetus throughout the whole pregnancy and at delivery
according to umbilical/plasma ratio—resulting in different
drug exposure, clinical SSRI maternal responsiveness,
and neonatal adverse outcomes. Given the high number
of polymorphisms involved in SSRIs metabolism, a
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TABLE 3 | Neonatal outcomes.
Controls
newborns
(n = 85)
SSRIs
newborns
(n = 42)
p-value
Neonatal sex NS
Female 41 (48.2%) 22 (52.4%)
Male 44 (51.8%) 20 (47.6%)
Preterm 4 (4.7%) 3 (7.1%) NS
Neonatal weight (gr) 3303.8 ± 431.0 3148.9 ± 593.5 NS
LBW 1 (1.2%) 6 (14.3%) 0.011
APGAR score at 1′ mean 9.7 ± 0.8 9.0 ± 1.3 0.006*
APGAR score at 1′ 0.017
†
6 0 3 (7.1%)
7 2 (2.4%) 4 (9.5%)
8 3 (3.5%) 5 (11.9%)
9 12 (14.1%) 8 (19.0%)
10 68 (80.0%) 22 (52.4%)
APGAR score at 5′ mean 10 ± 0.2 9.7 ± 0.6 0.023*
APGAR score at 5′ 0.013
†
8 0 3 (7.1%)
9 3 (3.5%) 6 (14.3%)
10 82 (96.5%) 33 (78.6%)
APGAR score at 1′ < 7 0 3 (7.1%) 0.069
UA pH 7.3 ± 0.1 7.3 ± 0.1 NS
UA BE −2.9 ± 3.6 −2.1 ± 4.9 NS
Data are presented as mean (± SD) or as number of women (%).
SSRIs, selective serotonin reuptake inhibitors.
Preterm, newborns of < 37 gestational age.
LBW, low birth weight. Birth weight of a liveborn infant of <2,500 g regardless of
gestational age.
UA, umbilical artery; BE, base excess.
*Student’s t-test.
†
Pearson’s chi-squared test (χ2 ).
study with a larger sample size and adequate power is
needed to draw conclusions that may be relevant in
clinical practice.
Several limitations do exist in this study. First, the low sample
size, but, on the other hand the main strength of this study is the
prospective approach. Than, the presence of major confounders
such as smoking, that was a relevant variable in this case-control
population. Nevertheless, it is well-known that smoking is much
more prevalent in women with depressive disorders in respect to
not depressed ones.
With regard to the pharmacogenetic aspect, only the
major causal variants in CYPs gene were taken into account,
without considering other genetic variants described to influence
CYPs expression and activity. Also, the genetic variability
was not explored, due to the differences in transporter-
dependent SSRI reuptake efficiency. Moreover, a control
group of depressed-not-treated women was not considered.
In a causal discussion, we could not ascertain that the
differences found were due to SSRI treatment and not to
the underlying psychiatric illness. Finally, drug compliance
was evaluated during obstetric and psychiatric visits every
TABLE 4 | Neonatal outcomes considering maternal and fetal genotype.
Maternal genotype Normal
(n = 12)
Altered
(n = 18)
Gestational age at delivery (week) 39.4 ± 1.7 38.9 ± 1.6
Preterm 1 (8.3%) 1 (5.6%)
APGAR sore at 1′ < 7 2 (16.7%) 0
APGAR score at 5′ < 7 0 0
Neonatal complications 9 (75.0%) 8 (44.4%)
Neonatal weight (gr) 3316.9 ± 667.6 3236.9 ± 579.5
LBW 1 (8.3%) 2 (11.1%)
UA ph 7.31 ± 0.1 7.29 ± 0.1
UA BE −2.9 ± 3.1 −1.8 ± 7.2
Fetal genotype Normal
(n = 10)
Altered
(n = 22)
Gestational age at delivery mean
(week)
39.1 ± 1.9 39.1 ± 1.4
Preterm 1 (10.0%) 1 (4.5%)
APGAR score at 1′ < 7 1 (10.0%) 1 (4.5%)
APGAR score at 5′ < 7 0 0
Neonatal complications 8 (80.0%) 9 (40.9%)
Neonatal weight (gr) 3065.0 ± 599.9 3355.7 ± 583.1
LBW 2 (20.0%) 1 (4.5%)
UA ph 7.3 ± 0.1 7.3 ± 0.1
UA BE −4.1 ± 4.6 −1.3 ± 5.8
Data are presented as mean (± SD) or as number of women (%).
Preterm: newborns of < 37 gestational age.
Neonatal complications: Low Birth Weight, a birth weight of a liveborn infant of <2,500 g
regardless of gestational age; Small for Gestational Age, infants with a birth weight below
the 10th percentile for gestational age; APGAR scores <7; neonatal breathing problems;
neurologic symptoms; respiratory distress syndrome; access to neonatal intensive care
unit; persistent pulmonary hypertension of the newborn; poor neonatal adaptation
syndrome; neonatal abstinence syndrome; transient tachypnea of the newborn.
LBW, low birth weight. Birth weight of a liveborn infant of <2,500 g regardless of
gestational age.
UA, umbilical artery; BE, base excess.
month, but real compliance could not be determined in
all cases.
CONCLUSIONS
This study confirms and expands previous data that correlate
SSRIs use during pregnancy to poor neonatal outcomes in terms
of LBW, low Apgar scores and, clinically, to PNAS. However,
poor neonatal outcome may also be related to untreated
psychiatric diseases. Therefore, identification of infants at risk of
PNAS is critical to child management since it could significantly
influence neonatal outcomes.
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